MU Department of Medicine 2011-2013 Annual Report Feb. 2014 | Page 54

54

Annual Report

University of Missouri- Columbia

funded research
Cardiovascular
Medicine

Kevin Dellsperger, MD, PhD

Co-Investigator

Co-Principal Investigator

Coordinator of A 104 week,

Mechanisms of Reperfusion-Induced

randomized, double-blind, placebo-

Kul Aggarwal, MD

Endothelial Dysfunction, National

controlled, parallel-group, multicenter

Principal Investigator

Institutes of Health, $250,000;

study to evaluate the efficacy of

PEGASUS TIMI-54 Study, $126,000,

10/01/2011 to 03/31/2012

aliskiren on the progression of
atherosclerosis in patients with

01/01/2011 to 12/31/2011
Co-Principal Investigator

coronary artery disease when added

Principal Investigator

Role of Cytokine-Induced Inflammation

to optimal background therapy,

Thrombin Receptor Antagonist to

in Endothelial Dysfunction in

AQUARIUS, $151,000, 12/08/2008 to

Reduce Events in Acute Coronary

Diabetes, National Institutes of Health,

12/31/2013

Syndrome, TRACER, $186,000,

$250,000, 10/01/2011 to 12/31/2012
William Fay, MD

06/24/2009 to 12/05/2012
Mary Dohrmann, MD

Principal Investigator

Principal Investigator

Principal Investigator

Roles of Plasminogen Activator

Thrombin Receptor Antagonist

Permanent Atrial Fibrillation Outcome

Inhibitor-1 and Vitronectin in Failure of

for Secondary Prevention of

Study Using Dronederone on Top of

Coronary Revascularization, National

Atherothrombotic Events, TRA2P/

Standard Therapy, PALLAS, $13,5000,

Institutes of Health (R01), $250,000,

TIMI-50, $150,610, 03/01/2008 to

09/20/2010 to 10/12/2012

09/01/2010 to 8/31/2014

12/14/2012
Greg Flaker, MD

Co-Investigator

Principal Investigator

Co-Investigator

Thrombosis and Hemostasis in Host

Improved Reduction of Outcomes:

Apixaban for Reduction in Stroke and

Defense from Bacterial Infection,

VYTORIN Efficacy International Trial.

Other Thromboembolic Events in

NIH/NHLBI Program Project Grant,

Simvastatin Vs Vytorin in Acute

Atrial Fibrillation, Aristotle, $332,688,

$223,863, 04/01/2009 to 03/31/2014

Coronary Syndromes, IMPROVE-IT

08/01/2007 to 10/28/2013
Co-Investigator

Study, $225,750, 03/02/2006 to
09/01/2020

Primary Investigator

Improved long-term biocompatibility

A Placebo-Controlled, Double Blind,

of coronary stents by plasma coating

Principal Investigator

Randomized, Multi-Center Study to

process, National Institutes of Health

Prevention with Ticagrelor of

Assess the Effects of Dronedarone

(R44), $282,614, 09/01/2011 to

Secondary Thrombotic Events in High-

400mg bid on Atrial Fibrillation

02/28/2014

Risk Patients with Prior Acute Coronary

Burden in Subjects with Permanent

Syndrome, PEGASUS-TIMI-54 Study,

Atrial Fibrillation, HESTIA, $26,800,

Co-Investigator

$126,000, 02/14/2011 to 02/13/2016

07/23/2010 to 11/19/2012

Prevention of Vein Graft Intimal
Hyperplasia with Human Apyrase,

Principal Investigator

Co-Investigator

National Institutes of Health (R44),

Randomized Evaluation of the

Permanent Atrial Fibrillation Outcome

$281,598, 10/01/2012 to 09/30/2013

Effects of Anacetrapib through Lipid-

Study Using Dronederone on Top of

Modification, REVEAL TIMI-55 Trial,

Standard Therapy, PALLAS, Sanofi-

Primary Investigator

$25,612, 03/07/2012 to 03/06/2017

Aventis, $97,140, 09/20/2010 to

Targeting Plasminogen Activator

10/12/2012

Inhibitor-1 t